Key Highlights

  • Third quarter 2026 Revenue rose 38% to $20.2 million from $14.6 million.
  • Gross Margin was 39.3%, compared with 23.8% a year earlier.
  • Net income was $3.7 million, compared with a net loss of $1.0 million.
  • The company completed the primary Investment phase of its operational excellence pillar.

Solésence, Inc. (NASDAQ:SLSN) reported financial results for the third quarter ended September 30, 2026, on November 12, 2026. The Romeoville, Illinois company positions itself as a provider of scientifically driven health care solutions across beauty and life science categories. Revenue, Gross Profit and Net Income all improved from the prior-year quarter, and management said the company completed the main investment phase of its operational work.

Revenue and Gross Profit

Third quarter revenue was $20.2 million, compared with $14.6 million in the same period of 2025. Gross profit increased to $7.9 million from $3.5 million, and gross margin rose to 39.3% from 23.8%. The release describes the company's revenue and margin gains as the product of its operational and strategic progress during the period.

Chief Executive Kevin Cureton said the company completed the primary investment and implementation phase of its first strategic pillar, operational excellence. He said the added capacity and efficiency will help the company meet Demand from Brand partners while scaling for future growth.

The company's revenue growth came across a period when it was completing capacity and efficiency investments, and management linked the gains to that work. Because the release reports revenue and gross profit side by side, readers can see that gross profit grew faster than revenue over the year, which is consistent with the margin expansion the company described.

Profitability and Financial Position

Net income for the quarter was $3.7 million, compared with a net loss of $1.0 million in the third quarter of 2025. Chief Financial Officer Laura Riffner said the company is pairing its revenue and net income gains with margin expansion. The company also presented results excluding certain items such as non-cash Equity compensation, which it said gives supplemental information to management and investors.

The release does not provide a full Balance Sheet summary, cash position or Debt figures in its headline section, so readers should consult the financial tables for those details.

Sector Context

Companies that blend beauty and life science products operate across consumer and clinical markets, which can have different margin profiles and sales cycles. Brand partners in these markets often value Manufacturing reliability and formulation innovation, and the ability to scale capacity is typically a central Factor in winning new business.

Solésence's emphasis on capacity and efficiency reflects that environment. Its gross margin expansion suggests its operational spending is starting to show up in product economics, although the release does not break out margins by product line.

For readers, the key facts are the change from a loss to net income and the step-up in gross profit, both of which the company attributes to the capacity and efficiency work completed during the period.

Risks and What Lies Ahead

The company's next phase depends on sustaining demand from brand partners and on keeping its cost structure in line with the expanded capacity. Management's forward-looking statements caution that results may differ from expectations, and consumer demand for beauty and life science products can shift quickly.

The company's strategic framework includes further pillars beyond operational excellence, along with continued innovation in novel formulations and expansion into global markets. Progress on those areas, and whether margin levels hold, will determine how well the company follows through on its stated goal of profitable long-term growth.

Management's commentary frames the next stage around demand from brand partners and continued formulation innovation. Keeping pace with that demand will require the expanded capacity to be used efficiently, and the company will need to show that the margin improvement holds as volumes change from quarter to quarter.

Final Word

The third quarter shows Solésence with a 38% revenue increase, a much higher gross margin and net income after a prior-year loss. The company has completed the main investment phase of its operational pillar and is now focusing on demand and further strategic milestones. Its ability to sustain margins as capacity is used will be the central question for its next reports.